Buy or sell Tempus stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies
Tempus Stock
Precision Medicine Solutions
About Tempus Stock
Tempus is a technology-enabled precision medicine solutions company that has built an operating system to battle cancer. It is on a mission to redefine how genomic data is used in a clinical setting. Their goal is for each patient to benefit from the treatment of others who came before by enabling physicians to deliver personalized cancer care for patients through interactive analytical and machine learning platform. Eric Lefkofsky founded it in 2015 and is headquartered in Chicago, Illinois.
Investors
Baillie Gifford
Flipkart, Ola, Spotify, goPuff, Indigo, Ginkgo Bioworks, Tempus, Scopely, Zymergen, Joby Aviation
SpaceX, Magic Leap, Tempus, Niantic, Symphony Communication Services, Ionic Security, Trifacta, Barefoot Networks, EasyPost
New Enterprise Associates
Robinhood, Databricks, Jet, Bloom Energy, Opendoor, Radiology Partners, Tempus, Scopely, Letgo, Automation Anywhere
Novo Holdings
Revolution
Tempus, Scopely, Aura, Sweetgreen, DraftKings, Tala, Optoro, BigCommerce, Uptake Technologies, Revolution Foods
T. Rowe Price
One97, Flipkart, WeWork, Cruise, Airbnb, Rivian, Magic Leap, Caris Life Sciences, Vroom, Ginkgo Bioworks
Funding History
| September 2015 | $10.0M |
|---|---|
| June 2016 | $10.0M |
| November 2016 | $10.0M |
| April 2017 | $30.0M |
| September 2017 | $70.0M |
| March 2018 | $80.0M |
| August 2018 | $111M |
| April 2019 | $200M |
| February 2020 | $97.3M |
| November 2020 | $409M |
Management
Chief Executive Officer
Eric Lefkofsky
Chief Financial Officer
Vanessa Rollings
Chief Technology Officer
Shane Colley
Press
bit - Aug, 5 2021
biospace - Jul, 28 2021
genomeweb - May, 21 2021
bioworld - Mar, 24 2021
genomeweb - Feb, 12 2021
medcitynews - Feb, 11 2021
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Tempus or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
